Brief: Hansa Biopharma Says Co's Biologics License Application (BLA) For Imlifidase Accepted By The FDA
18/02/2026 18:55
Feb 18 (Reuters) - Hansa Biopharma AB HNSA.ST: HANSA BIOPHARMA'S BIOLOGICS LICENSE APPLICATION (BLA) FOR IMLIFIDASE ACCEPTED BY THE FDA HANSA BIOPHARMA AB - TRIAL MET PRIMARY ENDPOINT WITH IMPROVED KIDNEY FUNCTION HANSA BIOPHARMA AB - A KEY SECONDARY ENDPOINT-DIALYSIS INDEPENDENCE AT 12 MONTHS-WAS ALSO STATISTICALLY SIGNIFICANT IN FAVOR OF IMLIFIDASE Source text: ID:nWkrC5r3Z Further company coverage: HNSA.ST ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS